A detailed history of Northern Trust Corp transactions in Janux Therapeutics, Inc. stock. As of the latest transaction made, Northern Trust Corp holds 266,498 shares of JANX stock, worth $15 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
266,498
Previous 194,373 37.11%
Holding current value
$15 Million
Previous $8.14 Million 48.7%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$35.29 - $50.26 $2.55 Million - $3.63 Million
72,125 Added 37.11%
266,498 $12.1 Million
Q2 2024

Aug 14, 2024

SELL
$35.12 - $64.78 $267,263 - $492,975
-7,610 Reduced 3.77%
194,373 $8.14 Million
Q1 2024

May 14, 2024

SELL
$7.93 - $49.75 $16,010 - $100,445
-2,019 Reduced 0.99%
201,983 $7.6 Million
Q4 2023

Feb 13, 2024

BUY
$5.85 - $11.7 $66,204 - $132,408
11,317 Added 5.87%
204,002 $2.19 Million
Q3 2023

Nov 13, 2023

BUY
$9.56 - $14.0 $51,576 - $75,530
5,395 Added 2.88%
192,685 $1.94 Million
Q2 2023

Aug 11, 2023

BUY
$11.08 - $15.92 $524,294 - $753,318
47,319 Added 33.81%
187,290 $2.22 Million
Q1 2023

May 15, 2023

BUY
$11.25 - $22.21 $2,733 - $5,397
243 Added 0.17%
139,971 $1.69 Million
Q4 2022

Feb 13, 2023

BUY
$11.1 - $18.26 $37,340 - $61,426
3,364 Added 2.47%
139,728 $1.84 Million
Q3 2022

Nov 14, 2022

BUY
$10.82 - $16.84 $34,699 - $54,005
3,207 Added 2.41%
136,364 $1.85 Million
Q2 2022

Aug 12, 2022

SELL
$9.52 - $15.65 $67,496 - $110,958
-7,090 Reduced 5.06%
133,157 $1.63 Million
Q1 2022

May 13, 2022

BUY
$13.24 - $20.24 $327,716 - $500,980
24,752 Added 21.43%
140,247 $2.01 Million
Q4 2021

Feb 08, 2022

SELL
$15.44 - $27.32 $22,635 - $40,051
-1,466 Reduced 1.25%
115,495 $2.28 Million
Q3 2021

Nov 15, 2021

BUY
$20.7 - $34.69 $2.42 Million - $4.06 Million
116,961 New
116,961 $2.53 Million

Others Institutions Holding JANX

About Janux Therapeutics, Inc.


  • Ticker JANX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 41,663,000
  • Market Cap $2.34B
  • Description
  • Janux Therapeutics, Inc., a biopharmaceutical company, develops therapeutics based on proprietary Tumor Activated T Cell Engager (TRACTr) platform technology to treat patients suffering from cancer. The company's lead TRACTr product candidates that are in preclinical or discovery stage target prostate-specific membrane antigen, epidermal growth ...
More about JANX
Track This Portfolio

Track Northern Trust Corp Portfolio

Follow Northern Trust Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Northern Trust Corp, based on Form 13F filings with the SEC.

News

Stay updated on Northern Trust Corp with notifications on news.